Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease
Rana T. Alhashimi(Virginia Commonwealth University), Martin K. Safo(Virginia Commonwealth University), Faik N. Musayev(Virginia Commonwealth University), Dina Alramadhani(Virginia Commonwealth University), Richmond Danso‐Danquah(Children's Hospital of Philadelphia), Nancy Anabaraonye(Children's Hospital of Philadelphia), Akua K. Donkor(Virginia Commonwealth University), Mohini S. Ghatge(Children's Hospital of Philadelphia), Osheiza Abdulmalik(Children's Hospital of Philadelphia), Tanvi Deshpande(Virginia Commonwealth University), Yan Zhang(Virginia Commonwealth University), Boshi Huang(Virginia Commonwealth University)
Cited by 7
Related Papers
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244
Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia
|Nature Communications|2016|212
G Protein–Coupled Receptor Deorphanizations
|The Annual Review of Pharmacology and Toxicology|2011|193